BIOGEN for BIOGEN
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, PET scan coverage and reimbursement, and dementia care Appropriations on Alzheimers screening and diagnosis H.R.19, Lower Costs, More Cures Act of 2021 H.R. 5376, Build Back Better Act
| Lobbyist | Covered position, as disclosed |
|---|---|
| AMY ABADIR New | — |
| JONATHAN CAUSEY | — |
| AMY DEMSKE | — |
| JOHN RAYMOND GIBSON | — |
| SUSAN KORNETSKY | — |
| CAROLINE TUCKER | — |
Pharmacy PHA
H.R.3/S.2543, Elijah E. Cummings Lower Drug Costs Now Act, discussions regarding support to increase Part B biosimilar payments from ASP +6% to ASP +8% of the reference product
| Lobbyist | Covered position, as disclosed |
|---|---|
| JONATHAN CAUSEY | — |
Medicare/Medicaid MMM
Discussions regarding Medicaid 340B drug discount program Reducing Out-of-Pocket Costs for Biosimilars in Medicare Part B Support for H.R. 6179, Directing CMS to implement a shared savings model for biosimilars
| Lobbyist | Covered position, as disclosed |
|---|---|
| AMY ABADIR New | — |
| AMY DEMSKE | — |
| TYLER HANSON New | Office of Rep. McNerney 6/2015 - 2/2017 |
| CAROLINE TUCKER | — |
Trade (domestic/foreign) TRD
IP/Trade TRIPS Waiver
| Lobbyist | Covered position, as disclosed |
|---|---|
| JONATHAN CAUSEY | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.